A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO

NCT07734844 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

910

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Macular Edema (DME)

Interventions

DRUG: Tabirafusp tedromer
DRUG: Aflibercept (2.0 mg)

Sponsor

Kodiak Sciences Inc